At the 15th Euretina Congress, results were presented by Praveen Patel, MD, consultant ophthalmic surgeon at Moorfields Eye Hospital, London, from a cohort study evaluating the use of a minimally invasive retrobulbar episcleral brachytherapy device developed by Salutaris Medical Devices, according to a company news release.
The presentation entitled, "Repeatability and limits of agreement for retinal and choroid thickness measures in patients with neovascular AMD," examined the importance of OCT derived measurements in clinic patients and in a large cohort. The study evaluated methods of measuring the posterior coat of the eye (including the sclera, choroid, and retina) to calculate appropriate patient-specific dosing and dwell times. Results from the study will be incorporated into a future SalutarisMD episcleral brachytherapy interventional study.
"To ensure accurate dosing, each patient should undergo individualized imaging to delineate treatment parameters and in most cases, a single data point is adequate to achieve a reliability of over 95%," Dr. Patel said.
The SalutarisMD device is designed to provide precise lesion-specific targeting. The procedure is performed using a hand-held instrument under the direct care and expertise of the treating retina specialist to deliver localized tissue irradiation, customized for each patient.